Literature DB >> 22222314

Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.

Norihito Moniwa1, Jasmina Varagic, Sarfaraz Ahmad, Jessica L VonCannon, Carlos M Ferrario.   

Abstract

BACKGROUND: Alterations in the circadian arterial pressure rhythm predict cardiovascular mortality. We examined the circadian arterial pressure rhythm and the effect of renin-angiotensin system blockade in congenic mRen2.Lewis hypertensive rats, a renin-dependent model of hypertension derived from the backcross of transgenic hypertensive [mRen-2]27 rats with Lewis normotensive ones.
METHODS: Twenty-nine mRen2.Lewis hypertensive rats were randomly assigned to drink tap water (vehicle; n = 9), valsartan (30 mg/kg/day; n = 10), or valsartan (30 mg/kg/day) combined with aliskiren given subcutaneously (50 mg/kg/day; n = 10) for 2 weeks. Arterial pressure, heart rate, and locomotive activity were recorded with chronically implanted radiotelemetry probes. The awake/asleep ratio was calculated as [awake mean arterial pressure (MAP) mean - asleep MAP mean)] / (awake MAP mean) x 100. Plasma renin activity (PRA) and concentration (PRC), and plasma and kidney angiotensin II (Ang II) were measured by radioimmunoassay (RIAs).
RESULTS: Untreated hypertensive rats showed an inverse arterial pressure rhythm, higher at day and lower at night, accompanied by normal rhythms of heart rate and locomotive activity. Treatment with valsartan or aliskiren and valsartan normalized the elevated arterial pressure and the arterial pressure rhythm, with the combination therapy being more effective in reducing MAP and in restoring the awake/asleep ratio. While PRA and PRC increased with the treatments, the addition of aliskiren to valsartan partially reversed the increases in plasma Ang II levels. Valsartan and the aliskiren and valsartan combination markedly reduced the renal cortical content of Ang II.
CONCLUSION: The altered circadian arterial pressure rhythm in this renin-dependent hypertension model uncovers a significant role of Ang II in the desynchronization of the circadian rhythm of arterial pressure, heart rate, and locomotive activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222314      PMCID: PMC3798054          DOI: 10.1177/1753944711434039

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN: 1753-9447


  76 in total

1.  Effect of upregulated renin-angiotensin system on per2 and bmal1 gene expression in brain structures involved in blood pressure control in TGR(mREN-2)27 rats.

Authors:  Jana Monosíková; Iveta Herichová; Boris Mravec; Alexander Kiss; Michal Zeman
Journal:  Brain Res       Date:  2007-09-06       Impact factor: 3.252

2.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

3.  Diurnal blood pressure pattern and risk of congestive heart failure.

Authors:  Erik Ingelsson; Kristina Björklund-Bodegård; Lars Lind; Johan Arnlöv; Johan Sundström
Journal:  JAMA       Date:  2006-06-28       Impact factor: 56.272

4.  Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats.

Authors:  Jewell A Jessup; Patricia E Gallagher; David B Averill; K Bridget Brosnihan; E Ann Tallant; Mark C Chappell; Carlos M Ferrario
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-06-09       Impact factor: 4.733

5.  Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.

Authors:  Jens Jordan; Stefan Engeli; Sam W Boye; Stephanie Le Breton; Deborah L Keefe
Journal:  Hypertension       Date:  2007-03-12       Impact factor: 10.190

6.  Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2. Lewis rat.

Authors:  Karl D Pendergrass; David B Averill; Carlos M Ferrario; Debra I Diz; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2006-01-10

7.  Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.

Authors:  Jean E Sealey; John H Laragh
Journal:  Am J Hypertens       Date:  2007-05       Impact factor: 2.689

8.  Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.

Authors:  J Nussberger; A H Gradman; R E Schmieder; R L Lins; Y Chiang; M F Prescott
Journal:  Int J Clin Pract       Date:  2007-06-22       Impact factor: 2.503

9.  Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.

Authors:  Michel Azizi; Joël Ménard; Alvine Bissery; Than-Tam Guyene; Alessandra Bura-Rivière
Journal:  Clin J Am Soc Nephrol       Date:  2007-08-08       Impact factor: 8.237

10.  Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies.

Authors:  Timothy R Smith; Thomas Philipp; Bernard Vaisse; George L Bakris; Margaret Wernsing; Joseph Yen; Robert Glazer
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738

View more
  8 in total

Review 1.  Mechanism of the circadian clock in physiology.

Authors:  Jacob Richards; Michelle L Gumz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-10       Impact factor: 3.619

2.  Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.

Authors:  Norihito Moniwa; Jasmina Varagic; Sarfaraz Ahmad; Jessica L VonCannon; Stephen W Simington; Hao Wang; Leanne Groban; K Bridget Brosnihan; Sayaka Nagata; Johji Kato; Kazuo Kitamura; R Ariel Gomez; Maria L Sequeira Lopez; Carlos M Ferrario
Journal:  Hypertension       Date:  2012-12-10       Impact factor: 10.190

3.  Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene.

Authors:  Carlos M Ferrario; Jessica VonCannon; Yan Jiao; Sarfaraz Ahmad; Michael Bader; Louis J Dell'Italia; Leanne Groban; Jasmina Varagic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-02-12       Impact factor: 4.733

4.  Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme.

Authors:  Sarfaraz Ahmad; Jasmina Varagic; Jessica L VonCannon; Leanne Groban; James F Collawn; Louis J Dell'Italia; Carlos M Ferrario
Journal:  Biochem Biophys Res Commun       Date:  2016-07-25       Impact factor: 3.575

5.  Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.

Authors:  Adam Whaley-Connell; Javad Habibi; Nathan Rehmer; Sivakumar Ardhanari; Melvin R Hayden; Lakshmi Pulakat; Caroline Krueger; Carlos M Ferrario; Vincent G DeMarco; James R Sowers
Journal:  Metabolism       Date:  2013-01-24       Impact factor: 8.694

6.  Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism.

Authors:  Norihito Moniwa; Jasmina Varagic; Stephen W Simington; Sarfaraz Ahmad; Sayaka Nagata; Jessica L Voncannon; Carlos M Ferrario
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-06-28       Impact factor: 4.733

7.  Relationship between arterial stiffness and circadian pattern of blood pressure.

Authors:  Jin-Sun Park; Joon-Han Shin; Jeong-Bae Park; Dong-Ju Choi; Ho-Joong Youn; Chang-Gyu Park; Jun Kwan; Youngkeun Ahn; Dong-Woon Kim; Se-Joong Rim; Seung-Woo Park; Jidong Sung; Jang-Ho Bae
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 8.  Circadian Control of Sodium and Blood Pressure Regulation.

Authors:  Reham H Soliman; David M Pollock
Journal:  Am J Hypertens       Date:  2021-11-20       Impact factor: 3.080

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.